lenalidomide
Amneal Receives FDA Approval for Lenalidomide
Amneal Pharmaceuticals Inc. has received approval from the FDA for its Abbreviated New Drug Application for ...
MARCH 5, 2025
Revlimid-Rituximab Combo Approved for FL and MZL
The FDA approved lenalidomide (Revlimid, Celgene) in combination with a rituximab product for previously treated ...
JUNE 4, 2019
Trial Is Assessing KRd Versus KCd in Newly Diagnosed MM Pts
Chicago—As an induction therapy in newly diagnosed, relatively young patients with multiple myeloma (MM), ...
JUNE 30, 2017
Long-Term Efficacy and Safety of ELd in RRMM Confirmed
Adding elotuzumab (Empliciti, Bristol-Myers Squibb) to lenalidomide (Revlimid, Celgene) and dexamethasone (ELd) ...
JUNE 26, 2017
Darzalex Approved With Pomalyst and Dex for Third-Line MM Rx
Approved in combination with pomalidomide (Pomalyst, Celgene) and dexamethasone for patients with multiple myeloma ...
JUNE 19, 2017
In High-Risk MM, Early Allo-HCT Appears Advantageous
San Diego—The trend of delaying allogeneic hematopoietic cell transplantation (allo-HCT) in multiple myeloma ...
MAY 4, 2017
FDA Expands Revlimid Indication for Multiple Myeloma
The therapy is approved for use as maintenance therapy following auto-HCT in patients with MM who received at least ...
FEBRUARY 23, 2017
Lenalidomide Maintenance May Extend PFS in CLL
Lenalidomide maintenance extended PFS after first-line therapy in high-risk CLL patients and after second-line ...
FEBRUARY 14, 2017
Monoclonal Antibody Adds Punch to Backbone of MM Rx
Adding the anti-CD38 monoclonal antibody daratumumab to the standard backbone MM regimen of ...
NOVEMBER 7, 2016
Lenalidomide Promising for Challenging T-Cell Leukemia/Lymphoma
Results from a small, Phase II study indicate that the oral immunomodulator lenalidomide induced a clinical ...
SEPTEMBER 28, 2016
OS Benefit Associated With Lenalidomide for Myeloma
Chicago—Maintenance lenalidomide extends the overall survival (OS) of patients with multiple myeloma by about ...
AUGUST 16, 2016
